| 76 | 6 | 12 |
| 下载次数 | 被引频次 | 阅读次数 |
目的了解新疆乌鲁木齐地区某农牧区丙型肝炎病毒(HCV)的感染现状。方法选取2012年度乌鲁木齐地区某农牧区世居的农牧民,采取整群抽样,收集血清标本6 000人份。用于本次丙肝血清学检测标本5 025人份,有效标本5 005人份用于数据分析,采用ELISA方法对收集血清的抗-HCV进行检测,通过SAS9.2软件统计分析,以频数、构成比(%)、阳性率(%)进行统计描述,参照全国抗-HCV阳性率,评价新疆乌鲁木齐地区人群抗-HCV阳性率水平。使用卡方检验分析不同年龄、性别、民族人群抗-HCV阳性率的差异;使用Logistic回归分析性别、年龄及民族对抗-HCV阳性率的影响。结果乌鲁木齐地区男性抗-HCV阳性率为1.01%,女性抗-HCV阳性率为0.93%,男性和女性抗-HCV阳性率差异无统计学意义。不同性别各年龄组人群抗-HCV阳性率差异无统计学意义。汉族人群抗-HCV阳性率为1.05%,哈萨克族人群抗-HCV阳性率为0.63%,回族人群抗-HCV阳性率为0.76%,维吾尔族人群抗-HCV阳性率为1.00%,不同民族人群的抗-HCV阳性率差异无统计学意义。不同民族各年龄组人群抗-HCV阳性率差异有统计学意义。经Logistic回归分析,年龄和民族与抗-HCV阳性率无关。结论新疆乌鲁木齐地区某农牧区的HCV感染属中-低流行区,但是仍高于全国总体水平。
Abstract：Objective To comprehend the infection status of hepatitis C virus(HCV)at an agricultural and pastoral zone in Urumqi area of Xinjiang.Methods Collected 6 000 serum samples of native farmers and herdsmen from the zone in 2012 by cluster sampling,and 5 025 serum samples were undergone anti HCV test with ELISA,in which 5 005 samples were effective.Statistical analysis was conducted by software of SAS9.2,describing with the frequency,the constituent ratio(%),the positive rate(%),and referring to the national anti-HCV positive rate to evaluate the rate in the zone.The difference of anti-HCV positive rate among different age,sex and nationality was analyzed by Chi square test,and the influence of gender,age and ethnicity on anti-HCV positive rate was analyzed by Logistic regression analysis.Results There was no significant difference between male and female in anti-HCV positive rate(1.01% vs 0.93%)in the zone,and no significant difference between age levels in different genders.Anti-HCV positive rate of HAN,Kazakh,HUI and Uyghur population were 1.05%,0.63%,0.76% and 1% respectively,which were no statistical significance among the ethnic groups.The difference of anti-HCV positive rate among age level groups in different ethnics was statistically significant.Concerning Logistic regression analysis,there was no correlation between age/ethnic and the anti-HCV positive rate.Conclusion HCV infection at an agricultural and pastoral zone in Urumqi area of Xinjiang is a low-mid endemic zone,but still higher than the national average.
[1]Infectious Disease and Parasitic Disease Branch.The Chinese Liver Disease Association.Prevention and treatment of hepatitis C[J].Chin J Hepatol,2004,22(2):131-136.
[2]DING J,YUE X R,ZhANG H M.Analysis on testing of elderly patients with hepatitis C[J].Lab Med Clin,2009,6(17):1474-1475.
[3]STRADER D B,WRIGHT T,THOMAS D L,et al.Diagnosis,management,and treatment of hepatitis C[J].Hepatology,2004,39(4):1147-1171.
[4]刘丽君,魏来.丙型肝炎病毒的流行病学[J].传染病信息,2007,20(5):261-264.
[5]任勤惠,瞿德敏,朱志议,等.新疆和四川部分地区不同民族献血者抗-HCV阳性率调查.[J].中国输血杂志,1995,2:96.
[6]MOHD-HANAFIAH K,GROEGER J,FLAXMANA D,et al.Global epidemiology of hepatitis C virus infection:new estimates of age-specific antibody to HCV seroprevalence[J].Hepatology,2013,57:1333-1342.
[7]LAVANCHY D.The global burden of hepatitis C[J].Liver Int,2009,29(Suppl 1):74-81.
[8]李强,黄玉仙,陈良.慢性丙型肝炎:从发现到治愈[J].中华肝脏病杂,2016,24(9):708-711.
[9]Geneva:World Health Organization.Guidelines for the screening,care and treatment of persons with hepatitis infection[S].2014.ISBN:9789241548755.
[10]LEMOINE M,NAYAGAM S,THURSZ M.Viral hepatitis in resourcelimitedcountries and access to antiviral therapies:current and future challenges[J].Future Virol,2013,8:371-380.
[11]KENNY-WALSH E.Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin[J].N Engl J Med,1999,340:1228-1233.
[12]FREEMAN A J,DORE G J,LAW M G,et al.Hepatology.Estimating progression to cirrhosis in chronic hepatitis C virus infection[J].Hepatolgy,2001,34:809-816.
[13]LI JF,LIU S,REN F,et al.Fibrosis progression in interferon treatmentnaive Chinese plasma donors with chronic hepatitis C for 20years:a cohort study[J].Int J Infect Dis,2014,27:49-53.
[14]RAO H Y,SUN D G,YANG R F,et al.Outcome of hepatitis C virus infection in Chinese paid plasma donors:a 12-19-year cohort study[J].J Gastroenterol Hepatol,2012,27:526-532.
[15]BEDOSSA P,Opolon P.Natural history of liver fibrosis progression in patients with chronic hepatitis C[J].Lancet,1997,349:825-832.
[16]BARREIRO P,PINEDA J A,RALLON N,et al.Influence of interleukin-28Bingle-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virushepatitis C virus-coinfected patients receiving antiretroviral therapy[J].J Infect Dis,2011,203:1629-1636.
[17]LAWITZ E,POORDAD F,BRAINARD D M,et al.Sofosbuvir with peginterferon-ribavirin for 12weeks in previously treated patients with hepatitis C genotype 2or 3and cirrhosis[J].Hepatology,201 5,61(3):769-775.
[18]王成宝,吕桦,聂红明,等.慢性丙型肝炎患者1129例感染途径流行病学分析[J].中国公共卫生,2010,26(11):1426-1427.
[19]XIA X,LUO J,BAI J,et al.Epidemiology of hepatitis C virus infection among injection drug users in China:systematic review and meta-analysis[J].Public Health,2008,122(10):990-1003.
基本信息:
中图分类号:R181.3;R512.63
引用信息:
[1]何丽,林栋羚,姚玉红,等.新疆乌鲁木齐地区某农牧区丙型肝炎病毒血清流行病学研究[J].新疆医科大学学报,2017,40(08):1088-1092.
基金信息:
国际横向课题(ML29600)
2017-08-15
2017-08-15